A Phase 1 Study of Acalabrutinib in Japanese Adult Patients with Advanced B-cell Malignancies

Trial Identifier:	D8220C00001
Sponsor:	AstraZeneca
NCTID::	NCT03198650
Start Date:	June 2017
Primary Completion Date:	October 2022
Study Completion Date:	December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045
JP	Chuo-ku, JP, 104-0045

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company